RT Journal Article
T1 Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery
A1 Mela-Rivas, Virginia
A1 Martín-Reyes, Flores
A1 Oliva-Olivera, Wilfredo
A1 Cantarero-Cuenca, Antonio
A1 Sánchez-García, Ana
A1 Sancho-Marín, Raquel
A1 González-Jiménez, Andrés
A1 Tomé, Mónica
A1 Moreno-Ruiz, Francisco Javier
A1 Soler Humanes, Rocío
A1 Fernández-Serrano, José Luis
A1 Sánchez-Gallegos, María Pilar
A1 Martínez-Moreno, José Manuel
A1 Tinahones-Madueño, Francisco José
A1 García-Fuentes, Eduardo
A1 Garrido-Sánchez, Lourdes
K1 Obesidad - Cirugía
K1 Obesidad mórbida
K1 Adelgazamiento
K1 Marcadores bioquímicos
AB There is a strong association between obesity and adverse health outcomes [1]. A numberof conservative therapies have demonstrated limited efficacy with regard to weight lossand the management of comorbidities. Bariatric surgery has been regarded as the mostefficacious therapeutic approach for severe obesity, as it induces weight loss and modifiesmetabolism to control morbid obesity and systemic comorbidities [2]. However, there aresome discrepancies about it in the literature since 5-20% of the patients do not achieve asuccessful long-term weight loss [3,4]. Therefore, the identification of biomarkersassociated with successful weight loss following bariatric surgery would facilitate thedevelopment of personalized medicine, as well as enable the integration of additionalinterventions in cases where adequate weight loss is not anticipated. However, thespecific biomarkers that can predict surgical outcomes remain unclear, representing acrucial step in the advancement of personalized medicine.
AB In recent years, significant research has been conducted with the aim of identifying genesassociated with obesity. This research has sought to enhance our understanding of theunderlying mechanisms, identify new targets for clinical therapy, and facilitate the earlyprediction of metabolic complications and treatment response. Indeed, there is anaccumulating body of evidence that epigenetic regulation of gene expression representsa significant contributor to the variation in predisposition to obesity and associatedcomorbidities [5]. In this context, miRNAs have been demonstrated to regulate amultitude of cellular processes at the post-transcriptional level, including cell growth,proliferation, differentiation, DNA repair, and apoptosis [6]. Deregulation of miRNAprofiles has been associated with a number of pathological conditions [7-9]. Furthermore,miRNAs have been identified as a key regulator of various biological processesassociated with obesity, including inflammation, adipogenesis, adipocyte differentiation,metabolic integration, fat metabolism, and insulin sensitivity [10-11]. Although miRNAsact at the subcellular level, they can also be found in the circulatory system. Thebiological implications and physiological role of circulating miRNAs remain unclear,despite their potential involvement in intercellular communication. Consequently, thesemiRNAs have gained clinical and therapeutic relevance as novel biomarkers, withchanges in their profile indicating the presence of physio-pathological conditions [12].
AB A number of studies have indicated that specific stimuli can influence the miRNA profileof patients, thereby promoting health improvement. The intake of macronutrients, thecomposition of energy-restricted diets with varying carbohydrate and fat ratios, and thephysical condition of the individual all influence the pattern of circulating miRNAs [13-14]. In the context of bariatric surgery, some studies have demonstrated alterations inpostoperative circulating miRNA expression, which have been associated with animprovement in the metabolic state of patients [15]. However, given the geneticbackground of obesity, it is reasonable to hypothesize that predictors may be identifiedwithin the genetic context. Therefore, the present study aims to determine whether thecirculating miRNA profile can be used as a predictive biomarker for the success of abariatric surgery in patients with morbid obesity.
PB Elsevier
YR 2025
FD 2025-04
LK https://hdl.handle.net/10630/40716
UL https://hdl.handle.net/10630/40716
LA eng
NO Mela V, Martín-Reyes F, Oliva-Olivera W, Cantarero-Cuenca A, Sánchez-García A, Sancho-Marín R, González-Jimenez A, Tomé M, Moreno-Ruiz FJ, Soler-Humanes R, Fernández-Serrano JL, Sanchez-Gallegos P, Martínez-Moreno JM, Tinahones FJ, García-Fuentes E, Garrido-Sánchez L. Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery. Metabolism. 2025 Apr;165:156129. doi: 10.1016/j.metabol.2024.156129. Epub 2024 Dec 30. PMID: 39743042.
NO https://openpolicyfinder.jisc.ac.uk/id/publication/4794
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026